Medical News

RSS

HemoShear announces milestone in development of predictive drug safety systems

HemoShear, LLC, a leading developer of human-relevant systems for drug development and discovery, today announced an important milestone in the development of systems that predict safety of new drugs and chemicals.

19 Jul 2013

Highmark Health Services creates Accountable Care Alliance to improve health care in Western Pennsylvania

Highmark Health Services is helping to improve health care through the formation of the Accountable Care Alliance, designed to not only improve care, but to also make it more affordable for patients in Western Pennsylvania.

19 Jul 2013

Health Affairs July 2013 issue describes health success stories outside US

Health Affairs July 2013 issue describes health success stories outside USOne, by Sema Sgaier of the Bill & Melinda Gates Foundation, and colleagues, is titled "How The Avahan HIV Prevention Program Transitioned From The Gates Foundation To The Government Of India."

19 Jul 2013

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules.

19 Jul 2013

Ecological framework provides better understanding of health-related quality of life in Parkinson's patients

Bronfenbrenner's ecological systems theory emphasizes the development of a series of nested environment systems with which an individual interacts. These systems interact with the individual, and also affect the development of the individual.

19 Jul 2013

NGM Biopharmaceuticals announces completion of $50 million Series C financing

NGM Biopharmaceuticals, Inc. announced today the successful completion of a $50 million Series C financing to support advancing its portfolio of potential therapeutics for the treatment of diabetes, obesity and other cardio-metabolic diseases.

19 Jul 2013

Researchers develop new drug delivery technique for diabetes treatment

Researchers have developed a drug delivery technique for diabetes treatment in which a sponge-like material surrounds an insulin core. The sponge expands and contracts in response to blood sugar levels to release insulin as needed. The technique could also be used for targeted drug delivery to cancer cells.

19 Jul 2013

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

Bausch + Lomb, the global eye health company, and Mimetogen Pharmaceuticals Inc. today announced that Bausch + Lomb has acquired an option to license an investigational compound currently in Phase 2 development for the treatment of dry eye syndrome, a condition that affects millions of people worldwide.

19 Jul 2013

Boys more likely to receive HPV4 vaccine if their mothers receive flu shots, study finds

Boys are more likely to receive the quadrivalent human papillomavirus vaccine if their mothers receive flu shots or Pap screenings, according to a Kaiser Permanente study published in the American Journal of Public Health.

19 Jul 2013

Aquavit Pharmaceuticals signs licensing agreement with U-Bio Med for microneedle technology

Aquavit Pharmaceuticals, Inc. announces it has signed a definitive licensing agreement with U-Bio Med Inc., a medical technology device company in South Korea, for the worldwide commercialization of the company's microneedle device technology.

19 Jul 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the potential to modulate targets typically addressed by biologics, today announced the initiation of a drug discovery collaboration with a subsidiary of Alexion Pharmaceuticals, Inc., the global biopharmaceutical company focused on developing and commercializing life-transforming therapies for patients with life-threatening, ultra-rare disorders.

18 Jul 2013

Safe Life FZC employs NanoSeptic self-cleaning products to combat MERS outbreak

Safe Life FZC, a new breed of healthcare distributors based in United Arab Emirates, is employing the latest technology to combat dangerous outbreaks like the deadly Coronavirus or MERS (Middle East Respiratory Syndrome).

18 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Audentes Therapeutics closes $30 million Series A financing

Audentes Therapeutics, Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, today announced the closing of a $30 million Series A financing.

18 Jul 2013

Kolltan signs research agreement with CHOP for novel therapeutic approaches for neuroblastoma

Kolltan Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced a license and research agreement with The Children's Hospital of Philadelphia to commence a collaboration with Yaël Mossé, M.D, an internationally recognized clinician and scientist for her work studying the causes and novel therapeutic approaches for the treatment of children diagnosed with neuroblastoma.

18 Jul 2013

First Edition: July 18, 2013

Today's headlines include reports about the House vote to delay the health law's mandates as well as advance coverage of President Barack Obama's Thursday speech in which he touts the overhaul's benefits.

18 Jul 2013

Ablynx initiates additional Phase I studies with anti-RSV Nanobody ALX-0171

Activaero GmbH, the therapeutic area specialist for respiratory diseases focusing on novel, pharmacoeconomically meaningful treatment solutions, today announced that its partner Ablynx NV has initiated additional Phase I studies with its anti-RSV Nanobody ALX-0171 using Activaero's FAVORITE inhalation approach.

18 Jul 2013

Oncodesign receives AAALAC certification for Dijon-based research center

Oncodesign, a contract research laboratory for the discovery of new anticancer therapies, today announces that its Dijon-based research center has received AAALAC certification.

18 Jul 2013

Plague detection through anti-carbohydrate antibodies could lead to rapid diagnosis

Even today, the lives of humans and animals are claimed by plague. A new antibody-based detection method can be used to reliably and sensitively identify plague in patient serum and other biological samples.

18 Jul 2013

Medical News

HemoShear announces milestone in development of predictive drug safety systems

Highmark Health Services creates Accountable Care Alliance to improve health care in Western Pennsylvania

Health Affairs July 2013 issue describes health success stories outside US

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Ecological framework provides better understanding of health-related quality of life in Parkinson's patients

NGM Biopharmaceuticals announces completion of $50 million Series C financing

Researchers develop new drug delivery technique for diabetes treatment

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

Boys more likely to receive HPV4 vaccine if their mothers receive flu shots, study finds

Aquavit Pharmaceuticals signs licensing agreement with U-Bio Med for microneedle technology

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Safe Life FZC employs NanoSeptic self-cleaning products to combat MERS outbreak

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Audentes Therapeutics closes $30 million Series A financing

Kolltan signs research agreement with CHOP for novel therapeutic approaches for neuroblastoma

First Edition: July 18, 2013

Ablynx initiates additional Phase I studies with anti-RSV Nanobody ALX-0171

Oncodesign receives AAALAC certification for Dijon-based research center

Plague detection through anti-carbohydrate antibodies could lead to rapid diagnosis

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News